Grants for Special district governments - Health

This funding opportunity supports research to uncover genetic factors related to mental disorders in diverse populations, particularly those of non-European ancestry, while promoting community engagement and career development for early-career researchers.

Allergic reactions to drugs and vaccines are a serious public health concern. For the purpose of this notice of funding opportunity (NOFO), allergic reactions include not only IgE-mediated reactions, but other immune-mediated and largely unpredictable drug and vaccine reactions. Based on data from 2013-2014, each year in the United States there are an estimated 200,000 emergency department visits for adverse events related to antibiotics. In children 5 or younger, antibiotics cause more than half (56%) of estimated emergency department visits for adverse drug events and 82% of these visits are due to allergic reactions. Allergic reactions to antibiotics include immediate life-threatening reactions such as anaphylaxis, severe cutaneous reactions including Toxic Epidermal Necrolysis and Drug Reaction with Eosinophilia and Systemic Symptoms, and less severe reactions that still limit further use of the drugs. A label of antibiotic allergy leads to the use of alternative, frequently more expensive antibiotics, often with lower efficacy, which may contribute to antibiotic resistance as well as increased mortality and morbidity in hospitalized patients. While allergic reactions to vaccines are less common, the inability to receive a vaccine due to an allergy is problematic to the individual, and the perceived risk of allergic reactions to vaccines contributes to vaccine hesitancy creating a public health issue. Objectives The objective of this NOFO is to solicit innovative projects to study the mechanisms and management of vaccine or antibiotic drug allergy (research on allergic responses to anti-viral, anti-fungal and anti-parasitic drugs will also be considered). The scope of research into antibiotic or vaccine allergic reactions includes, but is not limited to, the following: IgE-mediated and other mechanisms of immediate allergic antibiotic or vaccine reactions Non-IgE-mediated urticarial reactions to antibiotics or vaccines Delayed-type hypersensitivity reactions to antibiotics or vaccines Severe cutaneous adverse antibiotic or vaccine reactions Biomarkers to identify people at risk for reaction or to confirm reactions to specific antibiotics or vaccines Host factors that may predispose to allergic reactions including, but not limited to, host microbiome, genetics, or inflammatory conditions Mechanisms by which specific infections may increase the risk of an allergic reaction to an antibiotic or vaccine Immunomodulatory approaches to treating or preventing immunologic adverse antibiotic or vaccine reactions A secondary objective of this NOFO is to expand the number of investigators working in the field of vaccine and antibiotic drug allergy. Early-stage investigators are encouraged to apply. UG3/UH3 phase transition and Milestones This funding opportunity is designed as a two-stage cooperative agreement in which Project Scientists from NIAID will work with the investigative team. It will support projects that are organized into a two-year UG3 phase followed by a three-year UH3 phase. The UG3 phase may include pilot, observational, or hypothesis-generating high-risk projects. Preliminary data may be helpful but are not required. The use of electronic health records to identify potential participants for mechanistic studies is allowed. The use of human samples such as those related to clinically indicated and routinely used interventions or tests is encouraged. The UG3 must include milestones to determine the success of the project at the end of this phase. Milestones may be negotiated or re-negotiated after award as this program includes the flexibility to quickly revise milestones and/or aims within the scope of the original peer-reviewed application. Following the completion of the UG3 phase, NIAID staff will review the progress made and make the determination on whether the project will continue to the UH3 phase. NIAID support for the UH3 is contingent upon progress made during the UG3 phase, meeting the milestones, programmatic priorities, the original UG3/UH3 peer review recommendations, and the availability of funds. Some projects might not transition from the UG3 to the UH3 phase. Projects supported by the UH3 phase are required to be hypothesis driven, mechanistic, and extend the work initiated by the UG3 phase. Program Director/Principal Investigator (PD/PI) Meeting Attendance A kick-off meeting and annual meetings will be organized by NIAID to facilitate interactions among recipients to share approaches, data, and methods, with the aim of developing a cadre of dedicated researchers to conduct antibiotic and vaccine allergy and advance mechanistic research. These meetings will convene yearly in the Rockville, Maryland area and will be held in person, though a virtual component will be available to allow broader participation from laboratory members. The PD/PI from each award is expected to attend the kickoff meeting and annual meetings in person. Applications that propose the following topics will be considered non-responsive and will not be reviewed: Adverse drug reactions that are predictable and/or related to pharmacologic properties of the drug such as toxicity or overdose Investigation into drugs that are not antibiotics or vaccines (however research on anti-viral, anti-fungal and anti-parasitic drugs is allowed) Investigations into Guillain-Barré Syndrome or drug-induced autoimmune reactions Investigations of central nervous system and other neurologic adverse responses Investigations into the pathogens rather than host allergic responses to the antibiotics or vaccines Applications that do not propose mechanistic research in the UH3 phase Vaccines that are administered via a route that is not the same route of administration as approved by the FDA Vaccines that are used as an immunotherapeutic (e.g. allergen immunotherapy) HIV/AIDS research

This funding opportunity supports collaborative research teams of diverse experts to tackle ambitious challenges in dental, oral, and craniofacial science, focusing on innovative solutions like non-opioid pain therapies and health disparity-reducing technologies.

This funding opportunity supports researchers in developing innovative tools to measure human behavior and synchronize these measurements with brain activity, aiming to advance our understanding of brain-behavior relationships and improve interventions for neurobehavioral conditions.

This funding opportunity supports researchers in analyzing existing oral health data or developing new statistical methods to improve data analysis, with a focus on establishing causal relationships rather than just identifying correlations.

The "Access and Manipulation of Brain Cell Subtypes Implicated in Aging and AD/ADRD" grant aims to fund innovative research strategies that use advanced tools to target and manipulate specific brain cells affected by aging, Alzheimer's Disease, and related dementias, in order to better understand these conditions and their impact on brain function.

This funding opportunity supports innovative research on how communication between mitochondria and the nucleus affects Alzheimer’s Disease and related dementias, inviting applications from universities, nonprofits, and other organizations.

The Eunice Kennedy Shriver National Institute of Child Health and Human Development intends to publish a Notice of Funding Opportunity (NOFO) to invite applications for a Data Coordinating Center to support the work of the research projects funded under the Stillbirth Research Consortium described in the companion announcement NOT-HD-24-009. This Notice is being provided to allow potential applicants additional time to develop meaningful collaborations, interdisciplinary teams, and prepare responsive applications. The NOFO is expected to be published in Summer 2024 with an expected application due date in Fall 2024. This NOFO will utilize the UM2 activity code. Details of the planned NOFO are provided below.

This funding opportunity supports U.S.-based institutions in planning and implementing clinical trials aimed at improving treatments for dental, oral, and craniofacial conditions.

The "Type 1 Diabetes TrialNet Clinical Network Hub" grant aims to support the coordination unit for clinical trials focused on preventing and intervening early in type 1 diabetes, by improving communication, outreach, and developing new strategies for better screening, recruitment, and retention of participants.

This funding opportunity supports organizations in developing career development and mentoring programs for early-career researchers from diverse backgrounds who are underrepresented in the biomedical and behavioral sciences.

The 2024 Environmental Stewardship Pillar - Innovation Grant aims to support innovative projects that address environmental challenges in Appalachian Ohio. The grant focuses on enhancing community engagement across energy, economics, environment, and health sectors, promoting the circular economy, and expanding local organizations' capacity to access larger funding pools. Projects should involve schools, nonprofits, businesses, and other community groups in sustainable initiatives that drive forward-thinking solutions for cleaner air, water, green energy adoption, and diesel emission reduction. At least $16,000 is available for awards. Eligible applicants include public and nonprofit organizations, as well as individuals or groups working with a fiscal sponsor. Applications must be submitted online by August 2, 2024, and additional required documents must be emailed to [email protected] by the same deadline. Grant decisions will be announced no later than September 30, 2024. For inquiries, applicants may contact Kelly Morman at [email protected] or call 740-753-1111.

This funding opportunity supports research using human-derived ex vivo models to explore how HIV interacts with addictive substances, focusing on their effects on the brain and immune system.

This funding opportunity supports research on how inflammasome activation affects neurocognitive disorders and immune function in individuals with HIV and substance use disorders, encouraging studies that explore the interactions between these factors.

This funding opportunity provides financial support for research projects that explore new treatments and interventions for Alzheimer’s Disease, related dementias, and age-related cognitive decline, encouraging innovative approaches and pilot studies to improve future clinical trials.

This funding opportunity supports late-stage preclinical studies using adult stem cells to advance regenerative medicine therapies, specifically for researchers who have previously received NIH funding in this area.

This funding opportunity supports partnerships between master's and Ph.D. institutions to enhance research training for diverse master's students, helping them transition into biomedical Ph.D. programs.

This grant provides funding for interdisciplinary research teams to explore the neural and behavioral aspects of benign urological conditions, aiming to improve understanding and treatment of these diseases.

This FOA will support integrated, interdisciplinary research teams that focus on examining dynamic circuit functions related to behavior, using advanced and innovative technologies. The FOA will support programs with a necessarily-synergistic, team science approach. Awards will be made for 5 years, with a possibility of one competing renewal. Applications should incorporate overarching principles of circuit function in the context of specific neural systems underlying sensation, perception, emotion, motivation, cognition, decision-making, motor control, communication, or homeostasis. Applications should incorporate theory-/model-driven experimental design and should offer predictive models as deliverables. Applications should seek to understand circuits of the central nervous system by systematically controlling stimuli and/or behavior while actively recording and/or manipulating relevant dynamic patterns of neural activity and by measuring the resulting behaviors and/or perceptions. Applications are expected to employ approaches guided by specified theoretical constructs, and are encouraged to employ quantitative, mechanistic models where appropriate. Applications will be required to manage their data and analysis methods in a framework that will be developed and used in the proposed U19 project and exchanged with other BRAIN U19 awardees for further refinement and development. Model systems, including the possibility of multiple species ranging from invertebrates to humans, can be employed and should be appropriately justified. Programs should employ multi-component teams of research expertise including neurobiologists, statisticians, physicists, mathematicians, engineers, computer scientists, and data scientists, as appropriate - that seek to cross boundaries of interdisciplinary collaboration. Applicants proposing to include human subjects with invasive neural recording must apply to the companion FOA, RFA-NS-XX-XXX.

The purpose of the Mentored Quantitative Research Career Development Award (K25) is to attract to NIH-relevant research those investigators whose quantitative science and engineering research has thus far not been focused primarily on questions of health and disease. The K25 award will provide support and "protected time" for a period of supervised study and research for productive professionals with quantitative (e.g., mathematics, statistics, economics, computer science, imaging science, informatics, physics, chemistry) and engineering backgrounds to integrate their expertise with NIH-relevant research. This Funding Opportunity Announcement (FOA) is designed specifically for applicants proposing to serve as the lead investigator of an independent clinical trial, a clinical trial feasibility study, or a separate ancillary clinical trial, as part of their research and career development. Applicants not planning an independent clinical trial, or proposing to gain research experience in a clinical trial led by another investigator, must apply to companion FOA.